Envestnet Asset Management Inc. decreased its stake in United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 1.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,221 shares of the biotechnology company’s stock after selling 496 shares during the period. Envestnet Asset Management Inc. owned approximately 0.11% of United Therapeutics worth $10,515,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. Cullen Frost Bankers Inc. purchased a new stake in shares of United Therapeutics in the second quarter worth about $26,000. Guardian Wealth Advisors LLC purchased a new stake in shares of United Therapeutics in the third quarter worth about $27,000. Ronald Blue Trust Inc. purchased a new position in United Therapeutics in the second quarter valued at about $28,000. Neo Ivy Capital Management purchased a new position in United Therapeutics in the second quarter valued at about $48,000. Finally, Quadrant Capital Group LLC boosted its holdings in United Therapeutics by 51.0% in the second quarter. Quadrant Capital Group LLC now owns 225 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 76 shares during the last quarter. Hedge funds and other institutional investors own 95.63% of the company’s stock.
United Therapeutics Stock Up 0.6 %
Shares of United Therapeutics stock opened at $249.76 on Monday. The company has a current ratio of 9.85, a quick ratio of 9.39 and a debt-to-equity ratio of 0.17. The business’s 50 day simple moving average is $262.92 and its 200-day simple moving average is $245.76. The stock has a market capitalization of $11.56 billion, a price-to-earnings ratio of 16.63, a PEG ratio of 1.78 and a beta of 0.63. United Therapeutics Co. has a twelve month low of $158.38 and a twelve month high of $283.09.
Wall Street Analyst Weigh In
A number of research analysts recently commented on UTHR shares. LADENBURG THALM/SH SH reduced their price target on United Therapeutics from $295.00 to $285.00 in a report on Thursday. The Goldman Sachs Group started coverage on United Therapeutics in a report on Monday, December 5th. They issued a “sell” rating and a $230.00 price target for the company. Wedbush increased their price target on United Therapeutics from $250.00 to $305.00 in a report on Thursday, November 3rd. UBS Group initiated coverage on United Therapeutics in a report on Tuesday, December 6th. They issued a “buy” rating and a $320.00 price target for the company. Finally, Oppenheimer upped their price objective on United Therapeutics from $325.00 to $375.00 and gave the company an “outperform” rating in a research note on Thursday, November 3rd. Two analysts have rated the stock with a sell rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $291.55.
Insider Activity at United Therapeutics
In related news, CEO Martine A. Rothblatt sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 22nd. The stock was sold at an average price of $246.77, for a total value of $1,974,160.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $32,080.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Martine A. Rothblatt sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 22nd. The stock was sold at an average price of $246.77, for a total value of $1,974,160.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $32,080.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 15th. The shares were sold at an average price of $196.31, for a total value of $2,355,720.00. Following the completion of the sale, the executive vice president now owns 36,397 shares in the company, valued at $7,145,095.07. The disclosure for this sale can be found here. Insiders have sold a total of 199,420 shares of company stock worth $52,271,649 in the last three months. 12.40% of the stock is owned by company insiders.
About United Therapeutics
United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.
Featured Stories
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- MarketBeat Week in Review – 2/20 – 2/24
- Carvana Skidding On Revenue Decrease, Heavy Debt Burden
- What Are Consumer Staples Stocks?
- Is Rocky Brands Dividend A Good Fit For Your Portfolio?
- Beyond Meat Stock Is Not Beyond Hope
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Get Rating).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
